Drugs / Huashibaidu granule
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05638672 | May 2023 → Jun 2024 | COVID-19 | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| — | NCT05711017 | Feb 2023 → Jan 2025 | pneumonia | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| — | NCT05501288 | May → Jun 2022 | COVID-19 | Shanghai Children's Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Huashi Baidu Granule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05638672 ↗ |
| Known as | HSBDG | “Chinese herb compound granule Huashi Baidu granule (HSBDG)” NCT05501288 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese herb compound granule Huashi Baidu granule (HSBDG)” NCT05501288 ↗ |
| Route | Oral | “receive oral HSBDG for 5 consecutive days” NCT05501288 ↗ |